COBRE P1: MOLECULAR MECHANISMS OF AURORA KINASE A DYSFUNCTION IN LUNG CANCER
COBRE P1: MOLECULAR MECHANISMS OF AURORA KINASE A DYSFUNCTION IN LUNG CANCER
批准号:
7960369
负责人:
SCOTT GERBER
金额:
$26.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2010-04-30
关键词:
BreastCenters of Research ExcellenceClinical TrialsColorectalComputer Retrieval of Information on Scientific Projects DatabaseDrug Delivery SystemsDrug resistanceEsophagealExhibitsFoundationsFunctional disorderFundingGoalsGrantInstitutionLung diseasesMalignant NeoplasmsMalignant neoplasm of lungMass Spectrum AnalysisMethodsMicrotubulesMolecularMolecular TargetNormal CellOncogenesPaclitaxelPerformancePhosphopeptidesPhosphotransferasesProcessProteinsProteomeProteomicsResearchResearch PersonnelResourcesSourceStomachUnited States National Institutes of Healthaurora kinaseaurora-A kinasehuman STK6 proteininhibitor/antagonistoverexpressionsmall moleculetumor
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
八年前,极光激酶A被归类为癌基因。这种蛋白在许多形式的癌症中都有高水平的表达,包括胃癌、结直肠癌、乳腺癌、食道癌和肺癌。事实上,多达86%的肺癌表现出Aurora A的不适当表达。仅仅过度表达这种蛋白就可以将某些正常细胞转化为肿瘤。重要的是,由高Aurora A激酶活性产生的肿瘤显示出对包括紫杉醇在内的靶向微管形成的药物的耐药性增加。事实上,目前正在进行极光激酶活性的小分子抑制剂治疗癌症的临床试验。然而,人们对该激酶的分子靶点知之甚少。这种转变是如何发生的?Aurora A正常功能以外的蛋白质是否参与了这一过程?目前这项提案的目标是利用高效质谱学、蛋白质组学定量策略和选择性磷酸肽富集法的组合能力,在蛋白质组范围内综合表征Aurora A激酶的底物。这些信息是我们可以开始了解不受调控的Aurora A激酶活性如何导致肺癌以及如何治疗它的关键基础。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Eight years ago, Aurora kinase A was classified as an oncogene. This protein has been found at high levels in many forms of cancer, including gastric, colorectal, breast, esophageal and lung cancers indeed, as many as 86% of lung cancers exhibit inappropriate expression of Aurora A. Simply overexpressing this kinase can transform certain normal cells into tumors. Importantly, tumors generated by high Aurora A kinase activity demonstrate increased resistance to drugs that target microtubule formation, including Taxol. In fact, clinical trials are currently underway for small molecule inhibitors of Aurora kinase activity in treating cancer. However, very little is known about the molecular targets of this kinase. How does this transformation occur? Are proteins outside of the normal function of Aurora A involved in this process? It is the goal of the current proposal to tap into the combined power of high performance mass spectrometry, quantitative strategies in proteomics, and selective phosphopeptide enrichment methods to comprehensively characterize substrates of Aurora A kinase, on a proteome-wide scale. This information is a critical foundation from which we can begin to understand how unregulated Aurora A kinase activity causes lung cancer, and how to treat it.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COBRE P1: MOLECULAR MECHANISMS OF AURORA KINASE A DYSFUNCTION IN LUNG CANCER
-
批准号:8359702
-
项目类别:
-
资助金额:$25.96万
-
财政年份:2011
-
负责人:SCOTT GERBER
-
依托单位:
COBRE P1: MOLECULAR MECHANISMS OF AURORA KINASE A DYSFUNCTION IN LUNG CANCER
-
批准号:8167470
-
项目类别:
-
资助金额:$26.53万
-
财政年份:2010
-
负责人:SCOTT GERBER
-
依托单位:
COBRE: PROTEOMICS FACILITY CORE
-
批准号:7960367
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2009
-
负责人:SCOTT GERBER
-
依托单位: